GGrantIndex
Sort

141,003 grants matching cytokine

Protection Against Inhalation Anthrax with Inactivated Spores

$997,616
Donald G. Guiney · University Of California, San Diego · U01 · FY2009 · AI

The Environmental Triggers of Diabetes (TEDDY) in Sweden

$997,608
Ake Lernmark · Lunds Universitet · U01 · FY2008 · DK

ErythroMer: Nanoscale BioSynthetic Red Cell Substitute

$997,590
Esma Alp · Kalocyte, Inc. · R44 · FY2024 · HL

Immunity and Healthy Aging

$997,557
Abbe N De Vallejo · University Of Pittsburgh At Pittsburgh · R01 · FY2009 · AG

Anti-HIV Microbicide: Cellulose Acetate Phthalate (CAP)

$997,525
New York Blood Center · P01 · FY2004 · HD

OTHER FUNCTIONS - PINCER-BASED IN-PROCESS ANALYZER FOR BIOLOGICS

$997,251
Ling Tian · Mediomics, Llc · N44 · FY2012 · CA

Targeting lipid rafts for treatment of asthma

$997,203
Yakov Kogan · Raft Pharmaceuticals, Llc · R44 · FY2024 · AI

Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease

$997,077
Charles T Roberts · Oregon Health & Science University · R01 · FY2025 · DK

All-Human Microphysical Model of Metastasis Therapy

$996,993
Linda G. Griffith · Massachusetts Institute Of Technology · UH3 · FY2016 · TR

Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

$996,926
Jeffrey S King · Virogenomics Biodevelopment, Inc. · R44 · FY2021 · AI

The Northeast Center for Agricultural Health

$996,761
John J May · Mary Imogene Bassett Hospital · U50 · FY2006 · OH

Systemic regulation of metastasis

$996,660
David Charles Lyden · Weill Medical Coll Of Cornell Univ · R35 · FY2022 · CA

Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

$996,486
Renee Lynn Shirley · Virogenomics Biodevelopment, Inc. · R44 · FY2022 · AI

XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain

$996,485
Raymond A. Chavez · Xalud Therapeutics, Inc. · U44 · FY2012 · NS

Multi-Omic Single-Cell System for Improved Combination Cancer Immunotherapy Monitoring and Implementation

$996,470
Timothy S McConnell · Isoplexis, Inc. · R44 · FY2019 · CA

Host Directed Orynotide for MDR Gram Negative Bacterial Infections

$996,458
Justin Blaine Schaal · University Of Southern California · R01 · FY2024 · AI

Immunomodulatory Therapy for Neuropathic Pain

$996,399
Ridong Chen · Apt Therapeutics, Inc. · R44 · FY2021 · NS

Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT

$996,228
Jay Edward Wrobel · Fox Chase Chemical Diversity Center, Inc · R44 · FY2020 · HL

Targeting leukocyte metabolism to treat human autoimmune disease

$996,128
Jay L Rothstein · Immunext, Inc. · R44 · FY2019 · AI

Subclinical Vascular Disease and Metabolic Abnormalities in MACS

$996,118
Wendy S Post · Johns Hopkins University · R01 · FY2011 · HL

Mechanistic studies on stress, brain inflammation and neuroprotection

$996,062
Juan M Saavedra · National Institute Of Mental Health · ZIA · FY2012 · MH

Innate Immune Protection by Clean Genome E. coli

$995,989
Frederick R Blattner · Scarab Genomics, Llc · R44 · FY2011 · AI

New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease

$995,987
Franco Vitaliano · Exqor Technologies, Inc. · R44 · FY2023 · AG

New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease

$995,987
Franco Vitaliano · Exqor Technologies, Inc. · R44 · FY2024 · AG

pRBC Contaminant Removal with Hemocompatible Porous Polymer Beads

$995,984
Phillip Chan · Cytosorbents, Inc. · R44 · FY2018 · HL